secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autonomix Medical, Inc. (AMIX)
CIK:        0001617867
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001437749-24-034326
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autonomix Q2 FY2025 net loss $2.8M; PoC trial shows 100% of lead-in patients off opioids at 4-6 weeks
--------------------------------------------------------------------------------

- Net loss of $2.8M for three months ended Sept 30, 2024 vs $6.0M loss same quarter last year; cash $5.2M.
- 100% of lead-in responders zero opioid use at 4-6 weeks post-procedure; 83% pain reduction at follow-up.
- 60% enrollment reached in pancreatic cancer pain PoC trial; 79% responder rate with zero opioid use at 7 days.
- Upcoming milestones: complete enrollment Q4 CY2024, topline data 1H 2025, FDA clearance targeted 1H 2027.
- R&D expense $1.2M (vs $0.5M YoY) driven by clinical trial and product development costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1617867/000143774924034326/0001437749-24-034326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1617867/000143774924034326/amix20241107_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer